Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow
Authors: Sudipto Dolui, John A. Detre, Sarah A. Gaussoin, Jennifer S. Herrick, Danny J. J. Wang, Manjula Kurella Tamura, Monique E. Cho, William E. Haley, Lenore J. Launer, Henry A. Punzi, Anjay Rastogi, Carolyn H. Still, Daniel E. Weiner, Jackson T. Wright, Jeff D. Williamson, Clinton B. Wright, R. Nick Bryan, Adam P. Bress, Nicholas M. Pajewski, Ilya M. Nasrallah
Journal: JAMA Neurology (2022)

<h3>Importance</h3> Antihypertensive treatments benefit cerebrovascular health and cognitive function in patients with hypertension, but it is uncertain whether an intensive blood pressure target leads to potentially harmful cerebral hypoperfusion. <h3>Objective</h3> To investigate the association of intensive systolic blood pressure (SBP) control vs standard control with whole-brain cerebral blood flow (CBF). <h3>Design, Setting, and Participants</h3> This substudy of the Systolic Blood Pressure Intervention Trial (SPRINT) randomized clinical trial compared the efficacy of 2 different blood pressure–lowering strategies with longitudinal brain magnetic resonance imaging (MRI) including arterial spin labeled perfusion imaging to quantify CBF. A total of 1267 adults 50 years or older with hypertension and increased cardiovascular risk but free of diabetes or dementia were screened for the SPRINT substudy from 6 sites in the US. Randomization began in November 2010 with final follow-up MRI in July 2016. Analyses were performed from September 2020 through December 2021. <h3>Interventions</h3> Study participants with baseline CBF measures were randomized to an intensive SBP target less than 120 mm Hg or standard SBP target less than 140 mm Hg. <h3>Main Outcomes and Measures</h3> The primary outcome was change in whole-brain CBF from baseline. Secondary outcomes were change in gray matter, white matter, and periventricular white matter CBF. <h3>Results</h3> Among 547 participants with CBF measured at baseline, the mean (SD) age was 67.5 (8.1) years and 219 (40.0%) were women; 315 completed follow-up MRI at a median (IQR) of 4.0 (3.7-4.1) years after randomization. Mean whole-brain CBF increased from 38.90 to 40.36 (difference, 1.46 [95% CI, 0.08-2.83]) mL/100 g/min in the intensive treatment group, with no mean increase in the standard treatment group (37.96 to 37.12; difference, –0.84 [95% CI, –2.30 to 0.61] mL/100 g/min; between-group difference, 2.30 [95% CI, 0.30-4.30;<i>P</i> = .02]). Gray, white, and periventricular white matter CBF showed similar changes. The association of intensive vs standard treatment with CBF was generally similar across subgroups defined by age, sex, race, chronic kidney disease, SBP, orthostatic hypotension, and frailty, with the exception of an indication of larger mean increases in CBF associated with intensive treatment among participants with a history of cardiovascular disease (interaction<i>P</i> = .05). <h3>Conclusions and Relevance</h3> Intensive vs standard antihypertensive treatment was associated with increased, rather than decreased, cerebral perfusion, most notably in participants with a history of cardiovascular disease. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01206062